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Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of
current research that has the potential to transform cancer diagnostics and therapeutics. In particular, miRNAs could provide
potential new biomarkers for prostate cancer, the most common cause of cancer in UK men. Current diagnostic tests for prostate
cancer have low specificity and poor sensitivity. Further, although many prostate cancers are so slow growing as not to pose a
major risk to health, there is currently no test to distinguish between these and cancers that will become aggressive and life
threatening. Circulating miRNAs are highly stable and are both detectable and quantifiable in a range of accessible bio fluids, thus
have the potential to be useful diagnostic, prognostic and predictive biomarkers. This review aims to summarise the current
understanding of circulating miRNAs in prostate cancer patients and their potential role as biomarkers.
PROSTATE CANCER NEEDS NEW BIOMARKERS
Prostate cancer is the most commonly diagnosed male cancer in
the Western world, with more than 40 000 cases in the United
Kingdom diagnosed annually, and its management would benefit
greatly from new biomarkers for diagnosis, prognosis and
treatment response. Prostate-specific antigen (PSA) detection in
serum is the current gold standard biomarker for diagnosis and
response to treatment, but it has well-known limitations as a
biomarker. In terms of a diagnostic marker, elevated serum PSA is
not specific to malignant prostate disease and 450% of men
undergoing biopsy following a raised PSA result are diagnosed with
prostate cancer, an unacceptably high false-positive rate given the
risks of biopsy. PSA testing also has a false-negative rate of
approximately 15% (Schroder and Roobol, 2009). PSA has little
value as a prognostic biomarker as screening detects indolent
tumours as well as those that are or will become life threatening.
The majority of men with prostate cancer die of other causes, and
the costs and morbidity associated with over-treating these
indolent prostate tumours amount to a significant public health
problem. In addition, up to a quarter of men treated with curative
intent for localised prostate cancer experience relapse within
5 years (Greene et al, 2004). This lack of sensitivity and specificity
of PSA testing has contributed to controversy over the value of
early detection. Two large multi-national randomised control trials,
the European Randomised Study of Screening in Prostate Cancer
and the Prostate, Lung, Colorectal and Ovarian Screening Trial
provided conflicting results as to whether PSA screening for
prostate cancer reduces mortality. In addition, it is unclear as to
whether PSA screening may actually contribute to over diagnosis
and overtreatment of prostate cancer (Schroder and Roobol, 2009).
There are a variety of tools to improve the clinical usefulness of
PSA by incorporating it with other markers into an algorithm. One
such scoring system—‘the Cancer of the Prostate Risk Assessment’
(CAPRA) score is used to aid clinical decisions regarding
treatments at the time of diagnosis, as a surrogate prognostic
biomarker (Cooperberg et al, 2005). This algorithm is based on
patient’s age, histological Gleason tumour grade, staging of the
tumour, percentage of biopsy cores positive for cancer at diagnosis
and the initial PSA level. The CAPRA score has been externally
and independently verified and is routinely used to guide treatment
choices, but this test algorithm also lacks specificity and sensitivity
(May et al, 2007).
Therapeutic decision-making in hormone refractory prostate
cancer is a challenge due to frequent and inconsistent changes in
serum PSA, patient symptoms and radiographic findings. A
decision to discontinue ineffective agents early decreases morbidity
from drug toxicity, reduces costs and allows the patient to try an
alternative therapy. Further, validation of a biomarker as a robust
surrogate end point to replace overall survival would also
potentially speed up the drug development pathway. To date,
circulating tumour cells have been shown to be the strongest
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independent predictor of overall survival, more predictive than
post-therapy PSA (de Bono et al, 2008). Given the recent findings
discussed below, in the near future micro-ribonucleic acids
(miRNAs) could have a role alongside circulating tumour cells
and PSA in prediction of response to therapy.
MIRNAS AS POTENTIAL BIOMARKERS
MiRNAs are short RNA molecules, on average 22 nucleotides long.
First discovered in 1993, they function as post-transcriptional
regulators that bind to complementary sequences on target mRNA
usually in the 30UTR. This usually results in translational
repression or mRNA degradation resulting in reduced levels of
encoded protein; however, they can also induce gene expression by
binding to complementary promoter sequences thus upregulating
translation (reviewed in Nicoloso et al, 2009). The system is
complex; genes can be targeted by multiple miRNAs and each
miRNA is able to target hundreds of transcripts either directly or
indirectly. To date, over 1900 mature human miRNAs have been
identified (Kozomara and Griffiths-Jones, 2011). The importance
of miRNAs in gene regulation is highlighted by the observation
that loss of Dicer, an RNase required for miRNA biogenesis, results
in embryonic lethality in mice (Bernstein et al, 2003). There is a
growing and an increasingly convincing body of evidence that
miRNAs are frequently overexpressed or downregulated in the
malignant process and that miRNAs may therefore function as
either oncomiRs, encouraging tumour growth, or tumour sup-
pressors, repressing tumour growth (reviewed in Heneghan et al,
2010).
MiRNAs may exert their aberrant activity either via quantitative
effects, such as a change in expression level or by qualitative effects
that occur when there are losses or gains to a recognition sequence
either within the miRNA or its target. The function of a given
miRNA is largely determined by the relative availability of the
target mRNAs, as such individual miRNAs can have disparate
effects in differing tissues, specifically cancers of different cellular
origin. An example of this is miRNA-125b, which has been shown
to be an oncomiR in prostate cancer and to act as a tumour
suppressor in ovarian and breast cancer (reviewed in Cortez et al,
2011).
Some of the innate properties of miRNAs make them highly
attractive as potential biomarkers. MiRNAs can be readily detected
in small volume samples using specific and sensitive quantitative
real-time PCR (qRT-PCR); they have been isolated from most
body fluids, including serum, plasma, urine, saliva, breast milk,
tears and semen and are known to circulate in a highly stable, cell-
free form (Cortez et al, 2011). They are highly conserved between
species, allowing the use of animal models of disease for pre-
clinical studies. Furthermore, tumour cells have been shown to
release miRNAs into the circulation (Taylor and Gercel-Taylor,
2008) and profiles of miRNAs are altered in the plasma and/or
serum of patients with cancer (Taylor and Gercel-Taylor, 2008).
ROLE AND TRANSPORTATION OF CIRCULATING MIRNAS
Although it is clear that miRNAs function as a mechanism for
post-transcriptional regulation, it has not been conclusively proven
whether their presence in circulation is simply a by-product of cell
degradation or whether are they actively secreted into the body
fluids to mediate intercellular gene regulation. A body of evidence
supports the hypothesis that miRNAs can be actively and
selectively secreted; for example, miR-1246 and miR-451 have
been found to be released by the breast cancer cell line MCF-7 but
not by the non-malignant mammary epithelial breast cell line
(Pigati et al, 2010).
Also in support of active secretion is the appropriate packaging
of miRNAs to facilitate circulation and protect them from
degradation in body fluids. MiRNAs in serum are resistant to
circulating ribonucleases and severe physicochemical conditions,
such as extended storage, freeze-thawing and extreme pH (Chen
et al, 2008; Mitchell et al, 2008). There are three known methods by
which miRNAs are packaged: in lipid vesicles, such as exosomes
and apoptotic bodies; bound by RNA-binding proteins, such as
nucleophosmin 1 and Argonaute 2; and associated with high-
density lipoprotein. Such packaging of miRNAs has a wider
relevance as it facilitates the transfer of miRNAs between
individuals as exemplified by the example of immune-related
miRNAs in breast milk in the first 6 months of lactation,
corresponding with the passive immunity gained from colostrum
in the first 6 months. The implication of these findings for
treatment is that miRNAs, packaged appropriately, could be given
orally and not digested (Iguchi et al, 2010). These structurally
diverse extracellular miRNA-containing entities may also allow
target enrichment and therefore improve the utility of miRNAs as
biomarkers. For example, extraction of tissue-specific exosomes
using protein surface markers could potentially enrich for a cancer-
specific miRNA population, as has been shown in ovarian cancer
(Taylor and Gercel-Taylor, 2008).
METHODOLOGICAL CHALLENGES IN MEASURING
CIRCULATING MIRNAS
A prerequisite to developing circulating miRNA-based diagnostics
is the ability to quantify miRNAs from plasma and serum with
sufficient sensitivity and precision. The accurate measurement of
these miRNAs has been associated with many challenges, including
those related to pre-analytic variation such as specimen collection,
factors influencing RNA extraction efficiency and technical issues
involved in successful qRT-PCR and data analysis and normal-
isation (Kroh et al, 2010).
Major reasons for the variation and lack of consistency in
circulating miRNA data to date are likely the many potentially
confounding variables in methodology of extraction and quanti-
fication of miRNAs and data analysis. For instance, the use of
blood plasma or serum: there is a higher risk of cellular
contamination when preparing plasma as the supernatant is
pipetted away from the cellular pellet. The type of anticoagulant
used: EDTA and citrate are acceptable, but heparin impedes the
qRT-PCR step. There is also considerable inter-sample variability
in both the protein and lipid content of each individual’s serum
and plasma, which could affect the efficiency of RNA extraction
and potentially introduce potential inhibitors to qRT-PCR. Other
variables of note that need to be standardised are the duration of
time between blood collection and processing. The actual isolation
of miRNAs from serum and plasma is relatively straightforward,
using a guanidinium–phenol extraction followed by either
precipitation of the miRNA-containing aqueous phase or
column-based purification (Kroh et al, 2010).
The main issues that remain unresolved in the measuring of
circulating miRNAs are normalisation, amplification and contam-
ination. Quantitating the amount of total miRNA in body fluid
specimens is not possible because of the extremely low concentra-
tions. In addition, there is no consensus on suitable small RNA
reference genes that could be used as internal controls for
biological variability; current protocols call for samples to be
processed from identical input volumes, then corrected for
technical variability using spiked-in synthetic non-human
(Caenorhabditis elegans) miRNA as a normalising control
(Mitchell et al, 2008; Kroh et al, 2010). Use of ‘invariant’ miRNAs
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as endogenous controls has been proposed by some investigators,
but biological variability may preclude this approach and no
consensus on which has been reached to date. Another area
requiring standardisation is the use of pre-amplification reagents to
increase the sensitivity of the qRT-PCR, used in some studies but
not in others. Lastly, quantification of valid miRNAs in the serum
can be grossly altered by contamination by miRNAs leaked from
cellular blood components, either through haemolysis during
sampling or processing or by carry-over of whole cells in the
serum/plasma. Given all the uncertainties surrounding miRNA
extraction and analysis, it is clear why miRNA analysis is yet to be
implemented in the clinic: until there is standardisation in
phlebotomy protocol, sample processing, miRNA extraction
methodology and reliable quantitation, the translatability of these
studies will be limited (Kroh et al, 2010). However, the studies
published to date do point towards miRNAs having a role in the
future of prostate cancer biomarkers and will form a solid base
upon which to design future studies based on consensus protocols.
MIRNAS AS DIAGNOSTIC BIOMARKERS IN PROSTATE
CANCER
The first report of miRNAs as potential diagnostic markers was in
2008. Mitchell et al (2008) probed a panel of miRNAs in the serum
of healthy men and those with advanced prostate cancer and found
that miR-141 was highly elevated in the cancer samples. Moreover,
miR-141 was found to correlate significantly with serum PSA levels
and could detect individuals with advanced prostate cancer with
60% sensitivity and 100% specificity. The fact that Mitchell et al
(2008) compared healthy controls with advanced (metastatic)
cancer could explain the difference with a later study by Yaman
Agaoglu et al (2011) who found that miR-141 was not higher in 26
patients with localised disease compared with 20 healthy
individuals. They did, however, find that miR-21 and -221 were
significantly higher in the early-stage disease compared with
controls. Later, Lodes et al (2009) used a custom microarray to
profile miRNAs in serum from patients with various cancer types.
Although they identified 15 miRNAs elevated in the prostate
cancer patients, the profile was unable to discriminate between
prostate cancer patients and those patients with other malignan-
cies, such as breast or colorectal cancer.
Recently high-throughput multiplexed qRT-PCR has been used
to identify miRNAs significantly altered in the serum of patients
with prostate cancer. Moltzahn et al (2011) compared 36 early-
stage prostate cancer patients immediately before prostatectomy
with 12 healthy men. Receiver operated curves generated for the
individual miRNAs showed that some possessed significant
diagnostic capability. Three—miR-93, miR-106a and miR-24—
showed consistently low levels in the healthy individuals vs high
levels in the cancer groups, respectively. Bryant et al (2012) found
12 miRNAs were altered in the circulation of 78 men with prostate
cancer compared with 28 healthy men—miR-107 had the greatest
fold change. Chen et al (2012) defined a five-miRNA panel
(downregulation of let-7e, let-7c and miR-30c, upregulation of
miR-622 and miR-1285) with diagnostic value, able to differentiate
between 80 patients with prostate cancer and 44 patients with
benign prostatic hyperplasia (area under the curve¼ 0.924).
A 2012 study by Selth et al (2012), which showed miR-141,
miR-298, miR-346 and miR-375 to be consistently elevated in
patients with advanced prostate cancer over healthy individuals, is
notable in that they identified these candidate miRs first in the
Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mouse
model of prostate cancer. The authors argue that this, also in light
of the process of cancer progression in this model in many respects
mirroring human disease and the extensive functional homology
between mouse and murine miRs, demonstrates the potential for
mouse models to be used in identification of circulating miR
biomarkers, although they also report six other miRs to be
upregulated in TRAMP mice but not the human cancer patients
(Selth et al, 2012).
Mahn et al (2011) found that miR-26a, miR-195 and let-7i were
increased in the serum of men with localised prostate cancer when
compared with men with benign prostatic hyperplasia (area under
the curve¼ 0.758); however, when compared with healthy
individuals none of the candidate miRNAs were significantly
altered. This study highlights the importance of age-matched
controls, as these miRNAs are likely to be altered with ageing and
hormonal state. This study also supports the tumoural association
of these miRNAs, as the levels of miRNA in prostate cancer tissue
were highly correlated with levels in the serum. Furthermore, levels
decreased significantly in the serum following surgery. This is of
particular relevance in prostate cancer, as some miRNAs (e.g.,
miR-141 and miR-27a) have been shown to be under androgen
control; therefore they are likely to be expressed at different levels
depending on the treatment undergone by the patient (Waltering
et al, 2011; Fletcher et al, 2012).
MIRNAS AS PROGNOSTIC BIOMARKERS IN PROSTATE
CANCER
As already discussed, current attempts to distinguish the subgroup
of prostate cancer patients who will relapse post ‘curative
treatment’ with metastatic disease is based on an evaluation of a
collection of markers, including PSA, Gleason score and histolo-
gical score. Brase et al (2011) set out to establish markers of
micrometastasis in prostate cancer by comparing serum from men
with primary prostate cancer with those with metastatic prostate
cancer. They found 69 miRNAs elevated in men with metastatic
disease; a subset of these was then measured in the men with
localised prostate cancer. Three—miR-141, miR-200b and
miR-375—were found to be elevated with increasing tumour stage
and Gleason score. A similar study conducted by Bryant et al
(2012) compared plasma from patients with localised prostate
cancer with patients with metastatic prostate cancer, and found
16 miRNAs, including miR-141, miR-200b and miR-375, to be
differentially expressed, and miR-141, miR-21 and miR-221 were
also significantly higher in serum of advanced vs localised prostate
cancer patients in the previously mentioned study by Yaman
Agaoglu et al (2011). Moltzahn et al (2011) compared serum
collected before treatment from 29 patients with differing CAPRA
scores. MiR-24 levels were found to decrease with increasing
CAPRA score, whereas miR-106a, miR-451 and miR-93 were
increased in association with the CAPRA score. In another study of
82 prostate cancer patients, miR-20a and miR-21 were significantly
increased in patients with a high-risk CAPRA score (Shen et al,
2012).
These prognostic biomarker studies highlight miR-141, miR-
200b and miR-375 as significant disease correlates, which could
potentially be used in a test at the time of diagnosis to identify
those patients with previously undetectable micrometastases.
Future studies with longitudinal follow-up would allow us to
compare initial serum miRNA levels at the time of localised disease
between the cohort that go on to develop metastasis and those that
do not.
MIRNAS AS PREDICTIVE BIOMARKERS IN PROSTATE
CANCER
Predicting a patient’s response to treatment would allow tailoring
of appropriate regimens and a reduction in treatment-induced
morbidity. Zhang et al (2011) looked specifically at levels of
miRNA and prostate cancer BRITISH JOURNAL OF CANCER
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miR-21 in patients with localised prostate cancer, androgen-
dependent prostate cancer (ADPC), castrate-resistant prostate
cancer (CRPC) and benign prostatic hyperplasia. Levels of this
miRNA were found to be significantly higher in CRPC and ADPC
in those patients with a PSA44 ngml 1. Most interestingly, four
CRPC patients who were resistant to docetaxel chemotherapy had
significantly higher miR-21 levels than the six patients with
responsive disease. Potentially, miRNAs or miRNA profiles could
be used to predict response to a given therapy and further could
give clues as to mechanisms of resistance.
The utility of miR-141 as a biomarker of treatment response was
assessed by Gonzales et al (2011) who directly compared it with
PSA and found both miR-141 and PSA had a sensitivity of 78.9%,
whereas the specificity of miR-141 was 68.8% compared with
87.4% for PSA in predicting clinical progression in 21 patients with
CRPC or ADPC receiving a range of therapies. This longitudinal
behaviour and predictive ability was most closely related to, but
still distinct from, PSA with a significant positive correlation
(R¼ 0.77, Po0.001). Although miR-141 does not add any
additional prognostic information, this study in a small cohort of
men highlights the potential of circulating miRNAs for evaluating
treatment efficiency.
MIRNAS AS TREATMENT TARGETS
The elucidation of those miRNAs involved in the pathogenesis of
prostate cancer could potentially help to identify targets for future
therapies. Some of the miRNAs discussed are elevated both in
circulation and in prostate tumour tissue, notably miR-375 and
miR-141. Szczyrba et al (2011) showed that miR-375 targets
SEC23a, a putative tumour suppressor, while MiR-141 is a member
of the miR-200 family, which targets the ZEB family of
transcription factors, which function to repress the epithelial-to-
mesenchymal transition, a key step in cancer metastasis (Gonzales
et al, 2011). It has also been shown that miR-27a targets the
tumour-suppressor prohibitin in both prostate cancer and gastric
cancer, and reducing its levels inhibited the growth of prostate
cancer cells (Liu et al, 2009; Fletcher et al, 2012). A complication is
that each miRNA potentially targets many different mRNAs, thus
manipulating a given miRNA could alter the protein products in
several signal transduction pathways resulting in potential off-
target effects. However, this could also constitute an advantage—
for instance, miR-27a targets several tumour-suppressor genes
(e.g., Prohibitin, Wee1, ZBTB10, FOXO1, reviewed in Fletcher
Table 1. Synopsis of results of published studies investigating the potential of circulating miRNAs as biomarkers of prostate cancer
Study design Upregulated miRNAs
Downregulated
miRNAs
Sample
type
Method Patient numbers Reference
Cancer vs benign 100, 125b, 141, 143, 296 Serum qRT-PCR 25 metastatic PCa vs
25 controls
Mitchell et al,
2008
16, 92a, 103, 107, 197,
34b, 328, 485-3p, 486-5p,
92b, 574-3p, 636, 640,
766, 885-5p
Serum MiR microarray 5 PCa vs 8 controls
(other cancers tested)
Lodes et al, 2009
221 Plasma qRT-PCR 28 PCa vs 20 controls Zheng et al, 2011
141, 298, 346, 375 Serum qRT-PCR 25 metastatic PCa vs
25 controls
Selth et al, 2012
346, 622, 940, 1285 let-7e, let-7c Plasma Illumina miR
microarray
25 PCa vs 17 BPH, then
validation in 80 PCa,
44 BPH and 54 HI
Chen et al, 2012
375, 141 181a-2 Plasma qRT-PCR 78 PCa vs 28 controls, then
16 metastatic vs 55
non-metastatic
Bryant et al, 2012
Localised cancer vs
metastatic cancer
9*, 141, 200b, 375, 516a Serum qRT-PCR 7 metastatic PCa vs
14 localised PCa
Brase et al, 2011
21 Serum qRT-PCR 50 PCa (20 localised, 20
ADPC, 10 HRPC) vs 6 BPH
Zhang et al, 2011
375, 141 181a-2 Plasma qRT-PCR 78 PCa vs 28 controls, then
16 metastatic vs 55
non-metastatic
Bryant et al, 2012
Cancer at different
stage/risks vs
benign
21, 221 Plasma qRT-PCR 51 PCa (18 localised, 8 locally
advanced, 25 metastatic)
vs 20 HI
Yaman Agaoglu
et al, 2011
93, 106a, 874, 1207 24, 26b, 30c, 223 Serum Multiplexed
qRT-PCR
36 PCa (12 low risk, 12
medium risk, 12 high risk)
vs 12 controls
Moltzahn et al,
2011
26a, 195, Let7i, 16 Serum qRT-PCR 45 (37 localised, 8 metastatic)
PCa vs 38 controls
(18 BPH, 20 HI)
Mahn et al, 2011
20a, 21 Plasma qRT-PCR 82 PCa assessing association
with CAPRA score
Shen et al, 2012
Abbreviations: ADPC¼ androgen-dependent prostate cancer; HRPC¼ hormone refractory prostate cancer; BPH¼benign prostatic hypertrophy; HI¼ healthy individuals; PCa¼prostate
cancer; qRT-PCR¼quantitative real-time PCR; miR¼microRNA; CAPRA¼Cancer of the Prostate Risk Assessment. *Where one hairpin miR precursor gives rise to two mature miRs, one from
each arm, an asterisk is used to denote the least predominant form.
BRITISH JOURNAL OF CANCER miRNA and prostate cancer
1928 www.bjcancer.com |DOI:10.1038/bjc.2013.192
et al. 2012) and thus inhibiting this miR could inhibit tumour
growth via several pathways. Further exploration of the functions
and targets of such miRNAs will reveal in time the viability of
miRNA targets as a therapeutic strategy.
CONCLUSION
There is considerable excitement surrounding the use of miRNAs
in the biomarker field, which is well founded given their stability
and relative ease of detection. MiRNAs with potential for use as
diagnostic, prognostic, predictive biomarkers or indeed as a target
for treatment are summarised in Table 1. However, currently their
use is limited by conflicting data between studies due to lack of
standardisation in methodology and the lack of suitable reference
genes for normalisation. It is unlikely that any single miRNA will
achieve the desired level of diagnostic or prognostic accuracy, as
evidence is increasing that increased levels of particular miRNAs
can be associated with several different types of tumour. We believe
it will not be long, however, before these challenges are overcome
and a miRNA-based diagnostic test is launched for prostate cancer,
as has recently been done for pancreatic adenocarcinoma
(Szafranska-Schwarzbach et al, 2011).
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